Eli Lilly announced it will acquire Ajax Therapeutics for up to $2.3 billion, extending its M&A run into oncology. Ajax’s lead asset is a next-generation JAK2 inhibitor being evaluated in a Phase 1 study in patients with myelofibrosis. The deal reinforces Lilly’s strategy of adding early clinical-stage biology with clear development pathways across hematology indications. Ajax’s program is intended to address JAK2-driven disease mechanisms in myelofibrosis, a category where differentiating efficacy and tolerability remain central. For the biotech market, the transaction underscores that large-scale in-licensing and takeouts are continuing even as investors focus on definable Phase 2/3 catalysts and manufacturability.